Menopur

Menotrophin, the active ingredient in Menopur, is a gonadotropin presented as an injectable solution for intramuscular or subcutaneous use. It treats infertility due to anovulation and is employed in assisted reproductive technology protocols to stimulate ovarian follicular development. By providing both follicle‑stimulating hormone (FSH) and luteinising hormone (LH) activity, it promotes the growth and maturation of ovarian follicles.

GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide through regulated distribution channels that ensure product integrity.

Menopur is a gonadotropin used in fertility treatment to stimulate ovarian function. Infertility due to anovulation: promotes follicular development to enable ovulation. Assisted reproductive technology (ART) protocols: supports controlled ovarian hyperstimulation for procedures such as in‑vitro fertilisation. Ovarian stimulation for IVF cycles: enhances the number of mature oocytes retrieved. Multiple follicle development in donor cycles: increases oocyte yield for egg donation programs.

Menopur may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Injection site reactions: pain, redness or swelling at the injection site. - Abdominal discomfort: bloating or mild pelvic pain. - Nausea: occasional feeling of sickness.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome (OHSS): can lead to fluid accumulation, thrombosis, or renal impairment. - Multiple pregnancy: increased risk of twins or higher-order gestations. - Allergic reaction (anaphylaxis): rare but potentially life‑threatening hypersensitivity.

When using Menopur, careful monitoring and specific safety measures are recommended. - Monitor ovarian response: perform serial ultrasounds and hormone assays to adjust dose. - Assess risk of OHSS: evaluate patient history and baseline estradiol levels. - Use under specialist supervision: treatment should be managed by reproductive endocrinologists. - Avoid in uncontrolled thyroid disease or hormone‑dependent tumors. - Discontinue if severe OHSS develops. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menopur can interact with other medicines, requiring attention to avoid or monitor effects.

Major Interactions (Avoid): - Concurrent use of other gonadotropins: may cause excessive ovarian stimulation. - Co‑administration with GnRH agonists in high doses: increases risk of severe OHSS. - Estrogen‑containing therapies: can alter response to Menopur.

Moderate Interactions (Monitor Closely): - Corticosteroids: may affect follicular development, monitor response. - Anticoagulants: increased risk of injection‑site bleeding. - Thyroid hormone therapy: may modify ovarian response.